



Sepsis is a common clinical syndrome characterized by in-
fection accompanied by systemic inflammation. The systemic 
inflammation (systemic inflammatory response syndrome 
– SIRS), which may be also related to non-infectious causes 
(Fig. 1), manifests itself as changes in temperature (>38ºC or 
<36ºC), tachycardia (>90 per minute), tachypnea (>20 per 
minute), or changes in white blood cell count in peripheral 
blood (<4000 or >12,000 cells per µl, or >10% immature 
forms of granulocytes [bands]). More recent publications point 
to other systemic manifestations of infection than the four 
original SIRS criteria, although lists of such manifestations 
are more difficult to use in clinical practise than the origi-
nal SIRS definition (Appendix) [1,2]. Once symptoms of tis-
sue hypo perfusion (elevated lactate or altered mental status), 
arterial hypotension, or other organ dysfunction occur due to 
the systemic manifestations of infection we are dealing with 
severe sepsis; when blood pressure remains decreased despite 
adequate fluid resuscitation we are faced with septic shock 
(Fig. 1) [2].
Well over half a million patients in the USA develop se-
vere sepsis each year. The mortality from severe sepsis or septic 
shock varies according to the severity of condition from 15% to 
over 50%. No other clinical syndrome occurs so often, so sud-
denly, and with such devastating results at the same time. It is 
estimated that in the US alone over 200,000 patients die each 
year sepsis and almost as many in Europe [1,3]. Extrapolating 
this number to Polish population would put the number of 
deaths at about 15,000 per year.
The recognition of the importance of severe sepsis and sep-
tic shock continues to grow. A group of clinicians interested 
in the sepsis management representing eleven international 
organizations came together in early 2000s to develop „Su-
rviving Sepsis Campaign guidelines for the management of 
severe sepsis and septic shock” first published in 2004 [4]. The 
recently published 2008 revision represents the most recent 
effort of this group, now sponsored by fourteen international 
organizations [5].
Key changes in the methodology of 
development of this revision of Surviving 
Sepsis Campaign guidelines
First, recognizing an increasing role of clinical practice 
guidelines in shaping clinical practice around the world and 
the methodological advances in guideline development, Sur-
viving Sepsis Campaign guideline panel implemented an even 
more transparent process that resulted in more evidence-based 
and clinically useful recommendations. The group repeated 
the same careful search and analysis of evidence that charac-
terized the first edition. A new systematic way of grading the 
quality of available evidence and strength of recommendations 
according to the GRADE system was used [6]. 
For each recommendation, the authors assessed whether 
the desirable effects of following their recommendation will 
outweigh the undesirable effects (harm, burden, and cost), or 
vice versa. If they were confident that desirable effects out-
weigh the undesirable ones, or vice versa, they made a strong 
recommendation for or against a particular management 
strategy. If the panel was not confident (e.g. best available evi-
dence was low-quality and thus there was uncertainty about 
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the magnitude of benefits or risks, or benefits and harms were 
closely balanced) they made a weak recommendation. In this 
document a “strong” recommendation is worded as “we rec-
ommend” and a weak recommendation as “we suggest.”
Another new development is the explicit identification of 
areas of controversies and disagreements. Please refer to the 
full text of the guidelines to find discussions of pros and cons 
for making particular recommendations and, where applica-
ble, a characterization of the level of disagreement with the 
presentation of voting results. 
The issue of potential conflict of interest that many guide-
line panels face was also directly addressed. Successful re-
searchers in the field and “content experts” are often involved 
in guideline development on behalf of professional organiza-
tions. In many cases, these same researchers and experts re-
ceive industry funding to conduct their research, consult, 
lecture, participate in industry scientific advisory boards, or 
provide other services. 
These relationships with industry may result in real or per-
ceived conflicts of interest. For this edition of “Surviving Sep-
sis Campaign guidelines” potential conflicts were addressed 
by identification of relationship with the industry, discussion 
of potential conflicts of interest during each of the panel meet-
ings, and an option to abstain from discussion or voting on 
particular recommendation. 
Because of the methodological rigour of selecting, analys-
ing, and describing the evidence, aiming at explicitness and 
transparency, and consideration given to potential conflicts 
of interest, we believe these new “Surviving Sepsis Campaign 
guidelines” provide the best current recommendations for the 
management of sepsis and septic shock.
Key issues and changes in clinical 
recommendations
Main impact of these new guidelines is more in reinforcing 
principles of sepsis management than in refining recommen-
dations related to specific medications. The most important 
single general principle in sepsis management remains the 
need for rapid assessment and treatment.
We all know that we need to act fast when confronted by 
patients with acute myocardial infarction. We strive to achieve 
“door to needle” time of 30 minutes and “door to cath lab” 
of 60 minutes, we use helicopters to transfer these patients to 
the nearest experienced and equipped center. We remember, 
however, less frequently that whichever therapy these patients 
receive, the benefits turn out to be less than we can gain by 
giving an appropriate antibiotic to a patient in septic shock 
one hour earlier than otherwise we would.
An observational study performed by Kumar et al. [7] be-
tween 1989 and 2004 among Canadian and US patients with 
septic shock (patients with decrease in blood pressure requir-
ing fluids and pressors) serves to reinforce this message. The 
median time to effective antimicrobial therapy was 6 hours 
(25–75th percentile: 2.0 to 15.0 hours). In other words 50% of 
septic shock patients received effective antimicrobial therapy 
within 6 hrs of documented hypotension, but it took longer in 
another 50%. If this delay appears unusual let us recall that 
in a pivotal study of rapid sepsis management by Rivers et al. 
[8], 10% of patients did not receive any antibiotic within first 
6 hours after randomization! Kumar et al. [7] observed that 
administration of an antimicrobial effective for an isolated or 
suspected pathogens within the first hour of documented hy-
potension was associated with a mortality rate of 21.1%. In 
contrast, patients who received an appropriate antimicrobial 
later than one hour after presentation suffered higher in-hospi-
tal mortality that those receiving therapy within the first hour 
(OR 1.67, 95% CI 1.12–2.48). Each hour of delay in antimi-
crobial administration over the subsequent 6 hours was associ-
ated with an average decrease in survival of over 7%! The time 
to antibiotic use was prognosticaly more important than the 
full range of differences in the APACHE score. Figure 2 rep-
resents the mortality of patients with septic shock in relation 
to the time when the therapy directed at isolated or suspected 
pathogens was initiated. 
The strongest evidence supporting rapid management of 
septic shock in addition to giving prompt antimicrobial thera-
py comes from the study by Rivers et al. [8]. The investigated 
management strategy –“early goal directed resuscitation” – 
was guided by physiological targets of central venous pressure, 
urine output, arterial blood pressure and central venous blood 
oxygen saturation, and consisted of rapid fluid infusion, va-
soactive drug use and blood transfusion. Although previous 
studies of increasing oxygen delivery to hypoperfused tissues 
had failed to show a difference in clinical outcomes, the appli-
cation of such management strategy during the first 6 hours in 
sepsis induced tissue hypoperfusion was associated with large 
survival advantage.
Recommendations related to the currently controversial 
topic of using corticosteroids in septic shock, recombinant hu-
Fig. 1. Severe inflammatory response syndrome, infection, and dif-





















severe sepsis, while ensuring prompt decision making regard-
ing initial treatment. All considerations surrounding diagnosis 
and treatment of sepsis and septic shock require widespread 
recognition of the problem at many different levels (patients, 
clinicians, and organizations), education of health care pro-
fessionals (multispecialty and multidisciplinary), and system 
changes allowing rapid delivery of evidence-based care. We 
hope that the new “Surviving Sepsis Campaign guidelines” 
and the supplementary education and implementation initia-
tives, including those conducted in Poland, will help to ac-
complish this goal. For more information on Surviving Sepsis 
Campaign performance improvement program, including its 
presence in Poland, please go to: www.survivingsepsis.org and 
www.sepsa.pl.
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man activated protein C (rhAPC) use and glycemic control 
in severe sepsis encountered much discussion and underwent 
some changes. Results of the recently published CORTICUS 
study [9] undermined the confidence of the panel that the ad-
ministration of corticosteroids brings more benefit than harm 
even among those most hemodynamically compromised. Al-
though corticosteroids are suggested in patients with blood 
pressure poorly responsive to fluid infusion and vasopressor 
therapy, this recommendation is weak and based on low qual-
ity (inconsistent) evidence.
Similar sequence of events occurred regarding use of 
rhAPC. The results of the earlier PROWESS study that en-
rolled patients at very high risk (30.8% mortality in the pla-
cebo group) appeared very strong and convincing (6% risk dif-
ference for mortality) [10] until a second study in a population 
with less severe disease (17% mortality in the placebo group) 
showed essentially no effect [11]. The guidelines currently 
suggest the use of rhAPC in patients with severe sepsis and 
clinical assessment of high risk of death, typically those with 
multiple organ failure or APACHE II score of 25 or more. A 
new study in patients with septic shock is ongoing. 
Finally the degree of enthusiasm for tight glucose control 
generated by the results of the first study by van den Ber-
ghe and colleagues [12] continues to be tempered by the risk 
of hypoglycemia confirmed in a second study from the same 
group conducted in critically ill medical patients [13] and by 
just published results of a study among septic patients that 
was stopped early due to high risk of hypoglycemia and lack 
of clear benefit [14]. The guidelines still strongly recommend 
glycemic control, but only a weak recommendation was for-
mulated about the level of control suggesting a target glucose 
level of less than 150 mg/dl (8.25 mmol/l) – not the 80–110 
mg/dl (4.4–6.0 mmol/l) tight control limits. Results of a large 
ongoing NICE-SUGAR trial in which patients are random-
ized to strict or more liberal glucose control are awaited [15]. 
Comprehensiveness is one of the goals of “Surviving Sepsis 
Campaign guidelines”, hence the recommendations are not re-
stricted to the specific management of sepsis, including source 
control, but take into account also other strategies of general 
treatment including prevention of ventilator associated pneu-
monia, venous thromboembolism, and gastrointestinal bleed-
ing, as well as the best approaches to ventilation and sedation, 
etc. There are questions that remain to be addressed in next 
iteration of the guidelines, such as the use of intravenous im-
munoglobulin in severe sepsis [16] or the impact of rapid re-
sponse teams on sepsis management [17]. 
More evidence and more controversies await us. As a re-
sult, we will conclude this editorial with a reminder that se-
vere sepsis and septic shock are more deadly in the short term 
than any other common disease with which we deal in clinical 
practice. Despite controversies that will never be eliminated, 
only replaced with different content area, we can likely make a 
tremendous impact ensuring that the treatments we currently 
believe to be the best for severe sepsis are instituted. Clinicians 
should maintain a high level of suspicion and vigilance identi-
fying patients with sepsis, rapidly recognize the progression to 
Fig. 2. Probability of death from septic shock depending on time to 
initiation of effective antimicrobal therapy (based on [7])
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Appendix.  Possible systemic manifestation of sepsis  
(based on [1])
General	variables:
–	 Fever	(temperature	>38.3°C)
–	 Hypothermia	(core	temperature	<36.0°C)	
–	 Heart	rate	>90/min	or	>2	SD	above	the	mean	normal	value		
for	age
–	 Tachypnea
–	 Altered	mental	status
–	 Significant	edema	or	positive	fluid	balance	(>20	ml/kg		
over	24	h)
–	 Hyperglycemia	(plasma	glucose	>140	mg/dl	[7.7	mmol/l])		
in	the	absence	of	diabetes
Inflammatory	variables:
–	 Leukocytosis	(WBC	count	>12,000	µl–1)
–	 Leukopenia	(WBC	count	<4000	µl–1)
–	 Normal	WBC	count	with	>10%	immature	forms
–	 Plasma	C-reactive	protein	>2	SD	above	the	mean	normal	value
–	 Plasma	procalcitonin	>2	SD	above	the	mean	normal	value
Hemodynamic	variables:
–	 Arterial	hypotension	(SBP	<90	mm	Hg,	MAP	<70,	or	a	SBP	
decrease	of	>40	mm	Hg	in	adults	or	<2	SD	below	mean		
normal	for	age)
Organ	dysfunction	variables:
–	 Arterial	hypoxemia	(PaO2/FiO2	<300)	
–	 Acute	oliguria	(urine	output	<0.5	ml/kg/h	for	at	least	2	h		
despite	adequate	fluid	resuscitation)
–	 Creatinine	increase	>0.5	mg/dl	[44	µmol/l])	
–	 Coagulation	abnormalities	(INR	>1.5	or	aPTT	>60	s)
–	 Ileus
–	 Thrombocytopenia	(platelet	count	<100,000	µl–1)
–	 Hyperbilirubinemia	(plasma	total	bilirubin	>4	mg/dl	[70	µmol/l])
Tissue	perfusion	variables:
–	 Hyperlactatemia	(above	the	upper	limit	of	lab	normal)
–	 Decreased	capillary	refill	or	mottling
Diagnostic	criteria	for	sepsis	in	the	pediatric	population	are	signs	
and	symptoms	of	inflammation	plus	infection	with	hyper-	or	
hypothermia	(rectal	temperature	>38.5°C	or	<35°C),	tachycardia	
(may	be	absent	in	hypothermic	patients),	and	at	least	one	of	the	
following	indications	of	altered	organ	function:	altered	mental	
status,	hypoxemia,	increased	serum	lactate	level	or	bounding	
pulses.
Abbreviations:	aPTT	–	activated	partial	thromboplastin	time,		
FiO2	–	fraction	of	inspired	oxygen,	INR	–	international	normalized	
ratio,	MAP	–	mean	arterial	pressure,	PaO2	–	pressure	of	oxygen	in	
arterial	blood,	SBP	–	systolic	blood	pressure,	SD	–	standard	
deviation,	WBC	–	white	blood	cells
